It is utterly important to determine a nature of PD-L1 positivity for each molecular and malignant kind of relapsed urothelial carcinoma, because targeting of PD-1/PD-L1 pathway on the membrane of neoplastic cells and on CD8+ T-suppressor cells possesses powerful potency for effective disease control [22]. The gene discussed is CD8A; the disease is urothelial carcinoma.